Table 1.
Baseline characteristics of patients treated with amikacin
| Baseline characteristics | N = 107 (%) |
|---|---|
| Sex, Female | 70 (65.4) |
| Age (Years), Mean (SD) | 58.3 (14.9) |
| Race | |
| Caucasian | 72 (67.3) |
| South Asian | 4 (3.7) |
| East Asian | 28 (26.2) |
| African | 3 (2.8) |
| Comorbidities | |
| COPD/Emphysema | 19 (17.7) |
| Previous TB | 13 (12.1) |
| Cystic fibrosis | 6 (5.6) |
| Asthma | 5 (4.7) |
| Autoimmune disorders | 5 (4.7) |
| Alpha 1 antitrypsin deficiency | 2 (1.9) |
| Sarcoidosis | 2 (1.9) |
| ABPA | 2 (1.9) |
| Allogenic stem cell transplant | 2 (1.9) |
| HIV infection | 1 (0.9) |
| Species | |
| MACa | 69 (64.5) |
| M. abscessus | 21 (19.6) |
| M. xenopi | 11 (10.3) |
| MAC and M. xenopi | 4 (3.7) |
| M. shimodei | 1 (0.9) |
| M. fortuitum | 1 (0.9) |
| AFB smear positive ever | 100 (93.5) |
| Aspergillus isolation | 39 (36.4) |
| CT pattern | |
| Nodular bronchiectatic | 55 (51.4) |
| Fibrocavitary | 40 (37.4) |
| Random nodules | 2 (1.9) |
| Consolidation | 0 (0) |
| Unclassifiable | 10 (9.3) |
| Cavity | 66 (61.7) |
| Indication for treatment | |
| First line | 39 (36.4) |
| Second line | 68 (63.6) |
SD Standard deviation, COPD Chronic Obstructive Pulmonary Disease, TB Tuberculosis, SLE Systemic Lupus Erythematous, ABPA Allergic Bronchopulmonary Aspergillosis, HIV Human Immunodeficiency Virus, MAC Mycobacterium avium complex, AFB Acid Fast Bacilli, CT Computed Tomography
aFive patients had Clarithromycin resistant MAC; MAC isolates were not identified to the species level prior to 2010, and so are reported as MAC herein